# A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)

> **NCT05526755** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **AstraZeneca** · enrollment: 188 (actual)

## Conditions studied

- Stage II-IIIB Non-small Cell Lung Carcinoma

## Interventions

- **DRUG:** Osimertinib 80 mg/40 mg

## Key facts

- **NCT ID:** NCT05526755
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-06
- **Primary completion:** 2029-11-22
- **Final completion:** 2029-11-22
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05526755

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05526755, "A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05526755. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*